Budesonide

The Healio Editors have compiled a list of the most-read news in pulmonology posted in September.

Inhaled budesonide twice daily administered early in the course of COVID-19 reduced the need for urgent medical care, according to results of the STOIC trial presented at the virtual European Respiratory Society International Congress.

A fixed-dose combination of albuterol and budesonide at 180/160 µg and 180/80 µg demonstrated significant benefits in patients with asthma, according to high-level results from the MANDALA and DENALI phase 3 trials.

New data from the phase 3 TYREE study demonstrate efficacy of a fixed-dose combination of budesonide and albuterol in a single pressurized metered-dose inhaler to prevent exercise-induced bronchoconstriction in individuals with asthma.

In patients with eosinophilic esophagitis, budesonide oral suspension improved histologic, symptomatic and endoscopic outcomes, according to research published in Clinical Gastroenterology and Hepatology.

Twice-daily budesonide oral suspension, or BOS, improved outcomes in pediatric patients with eosinophilic esophagitis, according to research presented at this year’s virtual American Academy of Allergy, Asthma and Immunology Annual Meeting.

Takeda Pharmaceutical announced the FDA accepted its new drug application and granted priority review fo r TAK-721, an investigational therapy budesonide oral suspension intended for the treatment of eosinophilic esophagitis.

Recent data showed that topical budesonide may be linked to a decrease in endoscopic strictures after endoscopic mucosal resection or endoscopic submucosal dissection.

How common is asymptomatic bowel involvement in patients with peripheral or axial SpA? Can we use NSAIDs in these patients? What’s the difference between sulfasalazine and mesalamine? Hear what a rheumatologist should know about IBD!

The FDA has approved triple inhaled therapy for maintenance treatment of patients with COPD, according to a press release from AstraZeneca.